The Benefits of Combining TPA and DNA in Complex Parenomonic Effusions

Mihair Paeumus is the CEO of BI Biosciences. The company has been developing TPA and DNA therapy for patients with complicated parenomonic effusions. He says there are some patients that probably would benefit from an earlier surgical referral before committing to the whole protocol of TPA and DNAs. Mihair, is there anyone you won't do these for? Are there contraindications that our listeners should be aware of where you wouldn't want them to get the enzymatic therapy?